Immatics Us, Inc.

Amgen Inc.

Yannick Bulliard

Melinda Mata

Mamta Kalra

Steffen Walter

Norbert Hilf

Sabrina Kuttruff-Coqui

Ali Mohamed

Monique Dao

Sarah Missell

Ian Nevin Foltz

Xiaoshan Min

Kathy Manchulenko

Marissa Mock

Agnieszka Kielczewska

Aleksandra Norwicka

Sue J Sohn

Aleksandra Nowicka

Sarah Missel

The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

Methods for expanding and activating γσ T cells for the treatment of cancer and related malignancies

The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.

WPRE mutant constructs, compositions, and methods thereof

A vector containing a first nucleotide sequence S1 encoding a protein Z1, a second nucleotide sequence S2 encoding a protein Z2, a third nucleotide sequence S3 encoding a protein Y1, and a fourth nucleotide sequence S4 encoding a protein Y2, in which Z1 and Z2 form a first dimer and Y1 and Y2 form a second dimer, in which the first dimer Z1Z2 is different from the second dimer Y1Y2.

Viral vectors and use thereof in adoptive cellular therapy

Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.

TIGIT and CD112R blockade

The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of &#x3b3;&#x3b4; T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of &#x3b3;&#x3b4; T cells while depleting &#x3b1;- and/or &#x3b2;-TCR positive cells. T cell populations comprising expanded &#x3b3;&#x3b4; T cell and depleted or reduced &#x3b1;- and/or &#x3b2;-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

Methods for expanding and activating &#x3b3;&#x3b4; T cells for the treatment of cancer and related malignancies

Growing community of inventors

Houston, TX, United States of America

Yannick Bulliard